论文部分内容阅读
BACKGROUND Gastroenteropancreatic neuroendocrine tumors(GEP-NETs)represent a relatively rare and heterogenous group of tumors.Currently available treatment options for patients with progressive GEP-NETs include lutetium(177 Lu)oxodotreotide(177 LuDotatate